Company: LGN
Filing Date: 2025-11-03
Form Type: DRS
Source: 0001193125-25-262782
Chunk: 184

Company: Legence Corp.
Filing Date: 2025-11-03
Form: DRS
Chunk 184
---
 Exit Interests.                                                                                                                                                                                                                            |

124

Confidential Treatment Requested by Legence Corp. Pursuant to 17 C.F.R. Section 200.83

| (3) | The Series A Profits Interests are not traditional options, and therefore, there is no exercise price or                                                                                                          
 expiration date, but rather any vested Series A Profits Interests participate in distributions attributable to the appreciation in the fair market value of Legence Parent after their respective dates of grant. |

Options Exercised and Stock Vested in the 2024 Fiscal Year In fiscal year 2024, our named executive officers did not vest in any stock awards or exercise any option awards. However, during fiscal year 2024, Messrs. Sprau, Butz, Barnes and Seki vested in 1,420; 408; 165; and 165 Time Interests, respectively. Fractional interests have been rounded to the nearest hundredth of a unit. Pension Benefits Our named executive officers did not participate in or have account balances in qualified or nonqualified defined benefit plans sponsored by us. Our board of directors or compensation committee may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best interest. Nonqualified Deferred Compensation Our named executive officers did not participate in or have account balances in nonqualified defined contribution plans or other nonqualified deferred compensation plans maintained by us. Our board of directors or compensation committee may elect to provide our executive officers and other employees with nonqualified defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interest. Potential Payments Upon Termination or a Change in Control The following table sets forth quantitative estimates of the benefits that would have accrued to each of our named executive officers if his employment had been terminated without cause or he resigned for good reason on December 31, 2024. Amounts below reflect potential payments pursuant to the employment agreements for such named executive officers.

| Name      |     | Cash      
 Severance 
 Benefits  
 ($)(1)    |           |     | Continued Health 
 Benefits         
 ($)(2)           |        |     | Value of      
 Accelerated   
 Equity Awards 
 ($)           |   |
| J. Sprau  |     |           | 1,164,375 |     |                  | 40,928 |     |               | — |
| S. Butz   |     |           |   792,640 |     |                  | 27